WO2000040592A8 - Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof - Google Patents

Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof

Info

Publication number
WO2000040592A8
WO2000040592A8 PCT/US1999/030266 US9930266W WO0040592A8 WO 2000040592 A8 WO2000040592 A8 WO 2000040592A8 US 9930266 W US9930266 W US 9930266W WO 0040592 A8 WO0040592 A8 WO 0040592A8
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acids
acid stable
blocked nucleic
therapeutic uses
modified end
Prior art date
Application number
PCT/US1999/030266
Other languages
French (fr)
Other versions
WO2000040592A1 (en
Inventor
Roderic M K Dale
Steven L Gatton
Amy Arrow
Original Assignee
Oligos Etc Inc
Roderic M K Dale
Steven L Gatton
Amy Arrow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oligos Etc Inc, Roderic M K Dale, Steven L Gatton, Amy Arrow filed Critical Oligos Etc Inc
Priority to EP99966442A priority Critical patent/EP1140966A1/en
Priority to AU21976/00A priority patent/AU2197600A/en
Priority to JP2000592300A priority patent/JP4688294B2/en
Priority to CA2357986A priority patent/CA2357986C/en
Publication of WO2000040592A1 publication Critical patent/WO2000040592A1/en
Publication of WO2000040592A8 publication Critical patent/WO2000040592A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present invention provides end-blocked nucleic acids, e.g., 2'-O-R, 2'-O-R-O-R, 3'-O-R, and 3'-O-R-O-R oligonucleotides, that exhibit significant low pH stability, nuclease resistance and optionally antibacterial properties. These low toxicity, highly specific, acid stable, end-blocked nucleic acids represent a novel and improved oligonucleotide structure for therapeutic treatments of diseases. The 3' and 5' acid stable, exonuclease resistant polymers of the invention are shown here to provide antibacterial effects when applied in vivo, e.g., applied topically to skin with actual sites of infection on dogs and humans.
PCT/US1999/030266 1998-12-30 1999-12-16 Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof WO2000040592A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99966442A EP1140966A1 (en) 1998-12-30 1999-12-16 Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof
AU21976/00A AU2197600A (en) 1998-12-30 1999-12-16 Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof
JP2000592300A JP4688294B2 (en) 1998-12-30 1999-12-16 End-blocked nucleic acids modified with an acid-stable backbone and therapeutic uses thereof
CA2357986A CA2357986C (en) 1998-12-30 1999-12-16 Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US22349898A 1998-12-30 1998-12-30
US09/223,498 1998-12-30
US35606999A 1999-07-19 1999-07-19
US09/356,069 1999-07-19

Publications (2)

Publication Number Publication Date
WO2000040592A1 WO2000040592A1 (en) 2000-07-13
WO2000040592A8 true WO2000040592A8 (en) 2000-11-09

Family

ID=26917847

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/030266 WO2000040592A1 (en) 1998-12-30 1999-12-16 Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof

Country Status (5)

Country Link
EP (1) EP1140966A1 (en)
JP (1) JP4688294B2 (en)
AU (1) AU2197600A (en)
CA (1) CA2357986C (en)
WO (1) WO2000040592A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2357950C (en) * 1998-12-30 2013-07-23 Oligo Therapeutics Inc. Therapeutic phosphodiesterase inhibitors
JP4999255B2 (en) 2001-07-10 2012-08-15 レイクウッド−アメディックス，インコーポレーテッド Oligonucleotide-containing pharmacological composition and use thereof
DE10361502A1 (en) * 2003-12-23 2005-07-28 Phenion Gmbh & Co. Kg Cosmetic or pharmaceutical preparations containing superstructure-forming nucleic acid sequences
JPWO2012070618A1 (en) 2010-11-24 2014-05-19 株式会社カネカ Amplified nucleic acid detection method and detection device
CN104254620B (en) * 2012-04-27 2022-11-08 株式会社钟化 Method for amplifying nucleic acid and method for detecting amplified nucleic acid
US20160068901A1 (en) * 2013-05-01 2016-03-10 Advanced Liquid Logic, Inc. Analysis of DNA
WO2015076356A1 (en) * 2013-11-22 2015-05-28 株式会社カネカ Short-chain rna detection method
US20170016894A1 (en) * 2015-07-15 2017-01-19 Orizhan Bioscience Limited Detection Comprising Signal Amplifier
WO2018195253A1 (en) * 2017-04-19 2018-10-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for bcl2 inhibition
US11104941B2 (en) * 2018-09-28 2021-08-31 Bioo Scientific Corporation 5′ adapter comprising an internal 5′-5′ linkage

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4037363A1 (en) * 1990-04-09 1991-10-10 Europ Lab Molekularbiolog New 2-O-alkyl nucleotide(s) and polymers contg. them - for nuclease-resistant anti-sense probes and to treat viral infection including herpes influenza and AIDS and cancer
US5658731A (en) * 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
JPH07501314A (en) * 1991-05-10 1995-02-09 ハイブライドン　インコーポレイテッド 3'-end-capped oligonucleotide
US5696248A (en) * 1994-06-15 1997-12-09 Hoechst Aktiengesellschaft 3'-modified oligonucleotide derivatives
IT1271684B (en) * 1994-07-22 1997-06-04 Consiglio Nazionale Ricerche ANTISENSE OLIGONUCLEOTIDES COMPLEMENTARY TO THE MESSENGER RNA OF THE HUMAN UROKINASE RECEPTOR
WO1996039414A1 (en) * 1995-06-01 1996-12-12 Hybridon, Inc. Novel base protecting groups for oligonucleotide synthesis
US5849902A (en) * 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides

Also Published As

Publication number Publication date
WO2000040592A1 (en) 2000-07-13
CA2357986C (en) 2014-02-11
JP4688294B2 (en) 2011-05-25
EP1140966A1 (en) 2001-10-10
AU2197600A (en) 2000-07-24
JP2002534434A (en) 2002-10-15
CA2357986A1 (en) 2000-07-13

Similar Documents

Publication Publication Date Title
EP1248791A4 (en) Antisense modulation of caspase 3 expression
CA2107709A1 (en) Calcium Agent for Plants
EP2253706A3 (en) Antisense modulation of kinesin-like 1 expression
WO2003008576A3 (en) Synthetic double stranded oligonucleotides for targeted inhibition of gene expression
CY1108165T1 (en) LOCAL USE OF NF-κB BATTERY FOR THE TREATMENT OF TREATMENT OF ATOPHIC SKIN
ATE460481T1 (en) METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE AND MEDICATION FOR THE THERAPY OF A TUMOR DISEASE
DZ3165A1 (en) Food or pharmaceutical composition used to prevent or treat hyperoxaluria.
WO2001048190A8 (en) Therapeutic uses of lna-modified oligonucleotides
DK1013661T3 (en) 2'-O, 4'-methylene bicyclonucleoside
EP2221376A3 (en) Antisense modulation of superoxide dismutase 1, soluble expression
EP1190099A4 (en) Antisense modulation of pi3k p85 expression
WO2000040592A8 (en) Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof
EP1015011A4 (en) Peptide nucleic acids having antibacterial activity
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
ATE328893T1 (en) ANTIBACTERIAL PROTONATED OLIGONUCLEOTIDES
EP1189918A4 (en) Antisense modulation of integrin beta 3 expression
WO2000069428A3 (en) Anionic polymers as toxin binders and antibacterial agents
WO2003023004A3 (en) Antisense modulation of fibroblast growth factor receptor 3 expression
WO2004078941A3 (en) Modulation of gene expression using dna-rna hybrids
WO2001029175A3 (en) Antisense modulation of fra-1 expression
EP1131332A4 (en) Antisense modulation of inhibitor-kappa b kinase-beta expression
SE9503117D0 (en) Novel use of padlock probes
AU3698297A (en) Compositions containing at least one nucleic acid and their applications in the biomedical field, particularly in gene therapy
WO2001031051A3 (en) Antisense modulation of protein kinase c-theta expression
EP1248633A4 (en) Antisense modulation of glycogen synthase kinase 3 beta expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WR Later publication of a revised version of an international search report
ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2000 592300

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase in:

Ref document number: 2357986

Country of ref document: CA

Ref country code: CA

Ref document number: 2357986

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 21976/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999966442

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999966442

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WD Withdrawal of designations after international publication

Free format text: US

WWW Wipo information: withdrawn in national office

Ref document number: 1999966442

Country of ref document: EP